Jpmorgan Chase & CO Terns Pharmaceuticals, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TERN
# of Institutions
136Shares Held
63.6MCall Options Held
413KPut Options Held
106K-
Orbimed Advisors LLC San Diego, CA7.62MShares$54.1 Million1.25% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.18MShares$43.9 Million6.22% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.1MShares$43.3 Million1.36% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT4.95MShares$35.1 Million3.41% of portfolio
-
Black Rock Inc. New York, NY4.12MShares$29.3 Million0.0% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $267M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...